Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 1
2007 2
2008 1
2009 1
2013 3
2014 6
2015 6
2016 12
2017 11
2018 14
2019 25
2020 18
2021 20
2022 25
2023 21
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. Lee DW, et al. Among authors: maus mv. Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Biol Blood Marrow Transplant. 2019. PMID: 30592986 Free article. Review.
The future of engineered immune cell therapies.
Irvine DJ, Maus MV, Mooney DJ, Wong WW. Irvine DJ, et al. Among authors: maus mv. Science. 2022 Nov 25;378(6622):853-858. doi: 10.1126/science.abq6990. Epub 2022 Nov 24. Science. 2022. PMID: 36423279 Free PMC article. Review.
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Hines MR, et al. Among authors: maus mv. Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. doi: 10.1016/j.jtct.2023.03.006. Epub 2023 Mar 9. Transplant Cell Ther. 2023. PMID: 36906275 Free article.
The Emerging Landscape of Immune Cell Therapies.
Weber EW, Maus MV, Mackall CL. Weber EW, et al. Among authors: maus mv. Cell. 2020 Apr 2;181(1):46-62. doi: 10.1016/j.cell.2020.03.001. Cell. 2020. PMID: 32243795 Free PMC article. Review.
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV. Choi BD, et al. Among authors: maus mv. N Engl J Med. 2024 Apr 11;390(14):1290-1298. doi: 10.1056/NEJMoa2314390. Epub 2024 Mar 13. N Engl J Med. 2024. PMID: 38477966
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Raje N, et al. Among authors: maus mv. N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226. N Engl J Med. 2019. PMID: 31042825 Free PMC article. Clinical Trial.
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.
Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, Utro F, Levovitz C, Jacobs RA, Slowik K, Danysh BP, Livak KJ, Parida L, Ferry J, Jacobson C, Wu CJ, Getz G, Maus MV. Haradhvala NJ, et al. Among authors: maus mv. Nat Med. 2022 Sep;28(9):1848-1859. doi: 10.1038/s41591-022-01959-0. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097221 Free PMC article.
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, Scarfó I, Leick MB, Grauwet K, Berger TR, Stewart K, Anekal PV, Jan M, Joung J, Schmidts A, Ouspenskaia T, Law T, Regev A, Getz G, Maus MV. Larson RC, et al. Among authors: maus mv. Nature. 2022 Apr;604(7906):563-570. doi: 10.1038/s41586-022-04585-5. Epub 2022 Apr 13. Nature. 2022. PMID: 35418687
173 results